Pharmaceutical Executive
Pharm Exec's 2011 Emerging Leaders celebration convened Oct. 6 in New York.
Pharm Exec's 2011 Emerging Pharma Leaders program convened in New York on Oct. 6 for a gathering of some of the best minds in the industry under age 45—where we recognize 30 executives from diverse backgrounds who hope to make a difference as the industry grapples with a future that is rift by uncertainty. With our cohost Cegedim Relationship Management, the day began with a Cegedim sponsored roundtable discussion on "lean management" principles and ended with a dinner celebration honoring the winners at the rooftop restaurant 220 FIFTH.
Emerging Leaders and Pharm Exec editors mingle at the outdoor cocktail reception.
Richard Gliklich, CEO, Outcome
Cegedim's Angela Miccoli, left, with Leigh-Ann Durant of EMD Serono
EPL Jessica Monroe of Johnson & Johnson with her husband Todd
Cegedim's Angela Miccoli with Soma Gupta of Pfizer
Angela Miccoli, President of the Americas for Cegedim, along with Editor-in-Chief William Looney, presented each of the Emerging Leaders with an award and a plaque incorporating their career profiles published in the June issue of Pharm Exec. The dinner also featured a guest speaker: Dr. Richard Gliklich, Professor at the Harvard Medical School and founder of Outcome Inc., a leader in the development of patient registries and other tools to build an observational database on drugs. He noted as a key trend for the future the growing size of trial data sets, whose veracity should be accompanied by "a healthy respect for their limitations" in guiding therapy decisions that will affect millions of patients—our industry's key constituency. – Jeff Schindler, Managing Editor
Cegedim's Angela Miccoli with David Stern of EMD Serono
L to R: Jeff Schindler, Managing Editor; Dave Esola, GM, Pharma/Science group; William Looney, Editor-in-Chief; and Jay Berfas, Group Publisher, Pharm Exec
Cegedim's Angela Miccoli with Steven Blum of Forest Laboratories
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.